Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 296 | 5q33.1 | CD74 | CD74 molecule | 2,5 |
| Mouse | 1 | 279 | 18 34.41 cM | Cd74 | CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) | |
| Rat | 1 | 280 | 18q12.1 | Cd74 | CD74 molecule | |
| Previous and Unofficial Names |
| HLA-DR-gamma | Ia-associated invariant chain | invariant polypeptide of major histocompatibility complex, class II antigen-associated | CD74 molecule, major histocompatibility complex, class II invariant chain | Cd74 molecule, major histocompatibility complex, class II invariant chain | CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) | CD74 antigen (invariant polypeptide of major histocompatibility complex |
| Database Links |
|
| Alphafold | P04233 (Hs), P04441 (Mm), P10247 (Rn) |
| CATH/Gene3D | 1.10.870.10, 4.10.800.10 |
| ChEMBL Target | CHEMBL4692 (Hs) |
| Ensembl Gene | ENSG00000019582 (Hs), ENSMUSG00000024610 (Mm), ENSRNOG00000018735 (Rn) |
| Entrez Gene | 972 (Hs), 16149 (Mm), 25599 (Rn) |
| Human Protein Atlas | ENSG00000019582 (Hs) |
| KEGG Gene | hsa:972 (Hs), mmu:16149 (Mm), rno:25599 (Rn) |
| OMIM | 142790 (Hs) |
| Pharos | P04233 (Hs) |
| RefSeq Nucleotide | NM_001025159 (Hs), NM_001042605 (Mm) |
| RefSeq Protein | NP_001020330 (Hs), NP_001036070 (Mm) |
| UniProtKB | P04233 (Hs), P04441 (Mm), P10247 (Rn) |
| Wikipedia | CD74 (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CD74 is a type II transmembrane glycoprotein which associates with the MHC class II α and β chains and directs the transport of class II molecules to lysosomal and endosomal compartments [3], where the invariant chain is degraded. CD74 is also involved in B cell maturation [8] and acts as a receptor for macrophage migration inhibitory factor (MIF) [6]. Based on findings that CD74 is expressed with high frequency in lymphomas [10], anti-CD74 monoclonal antibodies are being developed as immuno-oncology therapeutics. For example, the anti-CD74 antibody-drug conjugate STRO-001 (SP7675) is being developed by Sutro Biopharma as a potential treatment for B cell malignancies [7] including multiple myeloma (MM). STRO-001 was granted FDA orphan drug designation for MM in October 2018 [4]. |
| Cell Type Associations | ||||||
|
||||||
|
||||||
|
| Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
1. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]
2. Claesson L, Larhammar D, Rask L, Peterson PA. (1983) cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proc Natl Acad Sci USA, 80 (24): 7395-9. [PMID:6324166]
3. Cresswell P. (1994) Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol, 12: 259-93. [PMID:8011283]
4. FDA. antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable maytansinoid linker warheads. Accessed on 13/11/2018. Modified on 13/11/2018. www.accessdata.fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=654118
5. Kudo J, Chao LY, Narni F, Saunders GF. (1985) Structure of the human gene encoding the invariant gamma-chain of class II histocompatibility antigens. Nucleic Acids Res, 13 (24): 8827-41. [PMID:3001652]
6. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med, 197 (11): 1467-76. [PMID:12782713]
7. Li X, Abrahams C, Embury M, Yu A, Kahana J, Brown M, Narla RK, Barnes L, Schwartz E, Boylan J et al.. (2016) Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL). Blood, 128 (22): 464 Meeting poster. DOI: 10.1182/blood.V128.22.464.464
8. Matza D, Wolstein O, Dikstein R, Shachar I. (2001) Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program. J Biol Chem, 276 (29): 27203-6. [PMID:11371575]
9. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res, 11 (14): 5257-64. [PMID:16033844]
10. Zhao S, Molina A, Yu A, Hanson J, Cheung H, Li X, Natkunam Y. (2019) High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate. J Pathol Clin Res, 5 (1): 12-24. [PMID:30191677]
CD molecules: CD74. Last modified on 13/11/2018. Accessed on 19/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2840.
target has curated data in GtoImmuPdb
